Effects of Balovaptan on Health-Related Quality of Life of Adult Males With Autism Spectrum Disorder: **Results From a Phase 2 Randomized Double-blind Placebo-Controlled Study (VANILLA)**

Tom Willgoss, PhD¹; Lisa Squassante, MSc²; Federico Bolognani, MD, PhD²; Janice Smith, PhD²; Janice Sm ¹ F. Hoffmann-La Roche Ltd., Welwyn Garden City, UK; ² F. Hoffmann-La Roche Ltd., Basel, Switzerland

Objective

• The phase 2 VANILLA study investigated efficacy and safety of balovaptan, a selective V1a antagonist, in adult men with autism spectrum disorder (ASD) for the treatment of social and communication deficits. An exploratory objective was to evaluate the effect of balovaptan on health-related quality of life (HRQoL)

Methods

Background

aired social comm				
			Ability to engage sociall on family	y and impact
Deficits in se	mptoms of ASD ocial communication ocial interaction	K	Psychological/emotiona	l health
Restricted, r	repetitive patterns of nterests, or activities		Ability to live independe	ntly
		JOB	Impact on school, work,	and career
Stage 1 n = 15 1:2 placebo : balovaptan 1.1		Adult Male	n -	e ASD (N = 223)
Stage 1 n = 15 1:2 placebo : balovaptan 1. Placebo n = 5 Balovapta n =	.5 mg 1:2 placebo an 1.5 mg = 10 n = 38	Adult Male Inclusion Stage 2 n = 115	es With Moderate to Sever a Criteria: IQ ≥ 70, CGI-S ≥ sta g 1:2 placebo : b Placebo	e ASD (N = 223) 4, SRS-2 \geq 66 age 3 = 25 alovaptan 10 mg Balovaptan 10 mg n = 16
Stage 1 n = 15 1:2 placebo : balovaptan 1.1 Placebo n = 5 Balovapta n =	.5 mg 1:2 placebo an 1.5 mg = 10 Placebo n = 38	Adult Male Inclusion Stage 2 n = 115 to : balovaptan 4 m Balovaptar n = 72	es With Moderate to Sever a Criteria: $IQ \ge 70$, CGI-S \ge stand g 1:2 placebo : b Placebo n = 9	e ASD (N = 223) 4, SRS-2 \geq 66 age 3 = 25 alovaptan 10 mg Balovaptan 10 mg n = 16 Transitions from and an external data review. AUC
Stage 1 n = 15 1:2 placebo : balovaptan 1.1 Placebo n = 5 Balovapta n = 5	.5 mg 1:2 placebo 1:2 placebo n = 38 Assessment Social Responsiveness Sca	Adult Male Inclusion Stage 2 n = 115 to : balovaptan 4 m Balovaptar n = 72	es With Moderate to Sever a Criteria: $IQ \ge 70$, CGI-S \ge stand g 1:2 placebo : b Placebo n = 9 RS-2)	e ASD (N = 223) 4, SRS-2 \geq 66 age 3 = 25 alovaptan 10 mg Balovaptan 10 mg n = 16 Transitions from and an external
Stage 1 n = 15 1:2 placebo : balovaptan 1.4 Placebo n = 5 Balovapta n = n = n = n =	.5 mg 1:2 placebo an 1.5 mg = 10 Placebo n = 38	Adult Male Inclusion Stage 2 n = 115 to : balovaptan 4 m Balovaptar n = 72	es With Moderate to Sever a Criteria: $IQ \ge 70$, CGI-S \ge stand g 1:2 placebo : b Placebo n = 9 RS-2)	e ASD (N = 223) 4, SRS-2 \ge 66 age 3 = 25 alovaptan 10 mg Balovaptan 10 mg n = 16 Transitions from and an external data review. AUC – Severity; C _{max} ,
Stage 1 n = 15 1:2 placebo : balovaptan 1.1 Placebo n = 5 Balovapta n = mary Outcome Measures ial communication ety and tolerability	.5 mg 1:2 placebo Placebo n = 38 Assessment Social Responsiveness Sca Adverse events and clinical	Adult Male Inclusion Stage 2 n = 115 to : balovaptan 4 m Balovaptar n = 72 ale 2nd Edition (SF I and laboratory as	es With Moderate to Sever Criteria: IQ ≥ 70, CGI-S ≥ stand 1:2 placebo : b Placebo n = 9	e ASD (N = 223) 4, SRS-2 \ge 66 age 3 = 25 alovaptan 10 mg Balovaptan 10 mg n = 16 Transitions from and an external data review. AUC – Severity; C _{max} ,
Stage 1 n = 15 1:2 placebo : balovaptan 1.1 Placebo n = 5 Balovapta n = mary Outcome Measures ial communication ety and tolerability condary Outcome Measures	.5 mg 1:2 placebo n = 38 Placebo n = 38 Assessment Social Responsiveness Sca Adverse events and clinical Vineland™-II Adaptive Beha Aberrant Behavior Checklis State-Trait Anxiety Inventory	Adult Male Inclusion Stage 2 n = 115 to : balovaptan 4 m Balovaptar n = 72 ale 2nd Edition (SF I and laboratory as avior Scale 2nd Edition st (ABC); Repetitive	es With Moderate to Sever Criteria: IQ ≥ 70, CGI-S ≥ sta n 1:2 placebo : b Placebo n = 9 RS-2) sessments tion (Vineland™-II) Behavior Scale-Revised (RBS-F	e ASD (N = 223) 4, SRS-2 \ge 66 age 3 = 25 alovaptan 10 mg Balovaptan 10 mg n = 16 Transitions from and an external data review. AUC - Severity; C _{max} , quotient. An
Stage 1 n = 15 1:2 placebo : balovaptan 1. Placebo Balovapta	.5 mg 1:2 placebo an 1.5 mg Placebo n = 38 Assessment Social Responsiveness Sca Adverse events and clinical Vineland™-II Adaptive Beha Aberrant Behavior Checklis	Adult Male Inclusion Stage 2 n = 115 bo : balovaptan 4 m Balovaptar n = 72 ale 2nd Edition (SF I and laboratory as avior Scale 2nd Edi st (ABC); Repetitive y (STAI); Anxiety, De	es With Moderate to Sever a Criteria: IQ ≥ 70, CGI-S ≥ sta n 1:2 placebo : b Placebo n = 9 RS-2) sessments tion (Vineland™-II) Behavior Scale-Revised (RBS-F epression and Mood Scale	e ASD (N = 223) 4, SRS-2 \ge 66 age 3 = 25 alovaptan 10 mg Balovaptan 10 mg n = 16 Transitions from and an external data review. AUC – Severity; C _{max} , quotient. An

Age, IQ, and ASD Severity Measures at Baseline Were Generally Similar and Well Balanced Across Treatment Groups

		Balovaptan	Balovaptan	Balovaptan	
Mean ± SD	Placebo	1.5 mg	4 mg	10 mg	• B
n ^a	72	30	73	38	а
Age, y	24.7 ± 6.3	28.2 ± 7.7	24.4 ± 6.4	24.0 ± 5.0	W
WASI-IQ	96.6 ± 15.1	100.1 ± 17.5	99.5 ± 17.2	97.3 ± 17.8	er
CGI-S	4.4 ± 0.6	4.4 ± 0.6	4.4 ± 0.5	4.4 ± 0.6	
ADOS-2	13.3 ± 3.9	13.0 ± 3.7	13.1 ± 4.3	13.7 ± 4.0	• D
SRS-2 total t score (caregiver)	77.7 ± 7.4	78.0 ± 8.0	77.9 ± 7.3	75.4 ± 6.5	m
Vineland [™] -II (composite)	60.5 ± 13.4	56.4 ± 14.2	62.7 ± 12.7	60.6 ± 11.4	C
PedsQL Generic Core Scale total score	69.9 ± 14.7	71.1 ± 20.2	69.9 ± 15.4	69.4 ± 16.9	in
Psychosocial health summary score	67.8 ± 14.9	68.1 ± 22.3	66.9 ± 17.3	66.6 ± 19.7	C
Physical health summary score	73.9 ± 19.4	76.6 ± 19.2	75.2 ± 17.9	74.4 ± 17.7	ра
PedsQL Cognitive Functioning Scale	54.2 ± 22.5	58.1 ± 25.8	55.8 ± 23.3	58.3 ± 21.2	CC
PedsQL Family Impact Module total score	64.0 ± 19.8	61.0 ± 17.6	63.4 ± 16.0	58.3 ± 19.4	
Use of psychotropic agents, % (n) ^b					• Ba
Antipsychotics	14.7 (11)	28.1 (9)	16.9 (13)	25.6 (10)	ar
SSRIs	32.0 (24)	34.4 (11)	35.1 (27)	28.2 (11)	
ADHD medications	18.7 (14)	12.5 (4)	23.4 (18)	25.6 (10)	

• Study participants lived with (or had substantial periods of contact with) a caregiver who was willing and able to attend on-site visits when required, oversee the participant's compliance with protocol-specified procedures and study medication dosing, and report on the participant's status via completion of study assessments

• Caregivers responsible for completing key assessments were in relationship to the study participants: 75% mothers, 12% fathers, 5% other custodial adults, 4% teachers, and 4% other

Values are mean \pm SD unless otherwise noted. ^a Modified intention-to-treat (ITT) population.


^b Safety population: placebo, n = 75; balovaptan 1.5 mg, n = 32; balovaptan 4 mg, n = 77; balovaptan 10 mg, n = 39. ADHD, attention deficit hyperactivity disorder; ADOS-2, Autism Diagnostic Observation Schedule-2; SSRI, selective serotonin reuptake inhibitor; WASI-IQ, Wechsler Abbreviated Scale of Intelligence

Reference

International Meeting for Autism Research; May 10-13, 2017; San Francisco, CA. 3. Varni JW, et al. Med Care. 1999;37(2):126-139. 4. Varni JW, et al. Clinical Ther. 2012;134(4):980-992. 5. Varni JW,

• Participant HRQoL was assessed at baseline, week 6, and week 12 using the PedsQL Generic Core Scales v4.0, which has Young Adult (age 18–25 years) and Adult (age 2 6 years) versions. The scale assesses functioning in 4 domains: physical, emotional, social, and school/work, from which Total, Physical Health Summary (Physical Functioning), and Psychosocial Health Summary (Emotional, Social, and School Functioning) scores are derived • The PedsQL Family Impact Module and Cognitive functioning scale were used to assess impact of acute and chronic health conditions on parents and family, and cognitive functioning, respectively • A mixed model of repeated measurements was fitted, including main effects for baseline, treatment, visit, and stage (where a dose was administered in different stages), and baseline*visit, treatment*stage, treatment*visit, stage*visit, and stage*visit*treatment interactions. Visit was fitted as a repeated effect with an unstructured correlation structure. Estimates for the differences between balovaptan doses and placebo with associated 90% CIs and P values are provided for descriptive purposes only and without any confirmatory meaning


Results



^a Because HRQoL was an exploratory endpoint, *P* values are nominal. ITT population. Items are reversed scored and linearly transformed to a 0–100 scale, so that higher scores indicate better HRQoL

1. Center for Drug Evaluation and Research (CDER); U.S. Food and Drug Administration (FDA). The Voice of the Patient: Autism. https://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM594722.pdf. Accessed September 20, 2018. 2. Bolognani F, et al. Results of a phase 2 randomized double-blind placebo controlled study (VANILLA) investigating the efficacy and safety of a V1a antagonist (RG7314) in adult men with ASD. Presented at:

Presented at the American Academy of Child & Adolescent Psychiatry 65th Annual Meeting, October 22–27, 2018, Seattle, WA




- Clinically relevant differences^{4,5} were observed for balovaptan 10 mg

Conclusions

- with placebo, suggesting meaningful improvements in HRQoL
- findings across the age and gender spectrum of individuals with ASD

PedsQL Cognitive Functioning Scale Measures Cognitive **Functioning in Patients With Acute and Chronic Health Conditions** as Well as Healthy School and Community Populations⁶




^a Patient completed in the VANILLA study

Summary of Changes From Baseline at V Cognitive Functioning Scale			
PedsQL Cognitive Functioning Scale Score	Estimated Treatment Difference (90% CI)		
Balovaptan dose, mg			
1.5	-3.87 (-15.59, -7.85)		
4	2.10 (-3.68, 7.87)		

9.15 (1.81, 16.49) ^a Because HRQoL was an exploratory endpoint, P values are non Items are reversed scored and linearly transformed to a 0–100 scale, so that higher scores indicate better HROoL.

PedsQL Family Impact Module Scale Measures Impact of Acute and Chronic Pediatric Health Conditions on Caregivers and the Family⁷



Summary of Changes From Baseline at Week 12 in the PedsQL Family Impact Module, Total Score

PedsQL Family Impact, Total Score	Estimated Treatment Difference (90% CI)	Effect Size	P Value ^a
Balovaptan dose, mg			
1.5	-1.28 (-9.14, 6.59)	-0.08	0.79
4	0.75 (-4.12, 5.62)	0.05	0.80
10	-0.88 (-8.91, 7.14)	-0.05	0.85

^a Because HRQoL was an exploratory endpoint, nominal *P* values are provided for descriptive purposes only. ITT population. Items are reversed scored and linearly transformed to a 0-100 scale, so that higher scores indicate better HRQoL



Financial Disclosures

TW, LS, JS, LM, PF, OK, DU, KS, MdVR: Employees of F. Hoffmann-La Roche Ltd. FB: Employee of F. Hoffmann-La Roche Ltd. at the time of analyses and abstract submission

ClinicalTrials.gov, NCT01793441

Funding was provided by F. Hoffmann-La Roche Ltd. for the study and third-party writing assistance, which was provided by Dinakar Sambandan, PhD, of Envision


Pharma Group

This data is under consideration for publication

• The VANILLA trial showed positive trends of improvement in HRQoL with balovaptan 10 mg compared with placebo in adult men with ASD • Trends for improvement in the PedsQL Generic Core Scale and Cognitive Functioning Scale were observed with balovaptan 10 mg compared


• To fully determine the effect of balovaptan on HRQoL, ongoing and future studies will be critical to validate this signal and to extend these

Functioning Scale



Effect Size	P Value ^a
-0.16	0.58
0.12	0.55

0.56	0.04	
ominal. ITT population.		




- The module also measures caregiverreported family daily activities and family relationships
- Caregiver completed **Completion time:** 5–10 minutes

Change From Baseline to Week 12 in the PedsQL Family Impact Module Total Score

Trends for improvements from baseline at week 12 were observed in

the balovaptan 10 mg group compared with placebo on the Cognitive



No differences were observed between any dose of balovaptan and placebo at week **12** on the PedsQL Family Impact module total score

